Literature DB >> 7612157

Isradipine suppresses amphetamine-induced conditioned place preference and locomotor stimulation in the rat.

O Pucilowski1, A Płaźnik, D H Overstreet.   

Abstract

The locomotor activating and the reinforcing effects of psychomotor stimulants are considered to be correlated with and responsible for the development and maintenance of stimulant addiction. Experiments were conducted to examine the effects of isradipine, the L-type calcium channel inhibitor, on the d-amphetamine-induced (1 mg/kg IP) reinforcement (conditioned place preference) and locomotor stimulation. Isradipine dose-dependently (0.6, 1.2, 2.5 mg/kg IP) attenuated the reinforcing effect of amphetamine. Two higher doses completely blocked the induction of place preference. At these doses isradipine also prevented the increase in the number of intercompartment crosses that was observed in both amphetamine- and vehicle-treated controls. In an acute experiment, isradipine failed to affect locomotor activity on its own either in the place preference boxes or in the open field. Amphetamine increased the open field activity but did not change the number of crosses in the place preference boxes. Only the highest (2.5 mg/kg) dose of isradipine significantly suppressed amphetamine-induced hyperactivity in the open field. The present results suggest that isradipine interferes with amphetamine-derived reinforcement at doses lower than those needed to block the acute locomotor effects of amphetamine. Given the qualitatively similar, previously reported results with verapamil, we conclude that the antireinforcing effects of the L-type calcium channel blockers cannot be exclusively explained by the suppression of psychomotor stimulation. The present results further support the notion that the L-type calcium channel blockers may be effective against stimulant addiction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7612157     DOI: 10.1016/0893-133X(94)00080-J

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  5 in total

Review 1.  CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease.

Authors:  Shambhu Bhat; David T Dao; Chantelle E Terrillion; Michal Arad; Robert J Smith; Nikolai M Soldatov; Todd D Gould
Journal:  Prog Neurobiol       Date:  2012-06-15       Impact factor: 11.685

Review 2.  Biological treatments for amfetamine dependence : recent progress.

Authors:  Kevin P Hill; Mehmet Sofuoglu
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

3.  Amphetamine-Decreased Progesterone and Estradiol Release in Rat Granulosa Cells: The Regulatory Role of cAMP- and Ca2+-Mediated Signaling Pathways.

Authors:  Chung-Yu Chen; Chien-Rung Chen; Chiao-Nan Chen; Paulus S Wang; Toby Mündel; Yi-Hung Liao; Shiow-Chwen Tsai
Journal:  Biomedicines       Date:  2021-04-29

4.  Practical Radiosynthesis and Preclinical Neuroimaging of [11C]isradipine, a Calcium Channel Antagonist.

Authors:  Benjamin H Rotstein; Steven H Liang; Vasily V Belov; Eli Livni; Dylan B Levine; Ali A Bonab; Mikhail I Papisov; Roy H Perlis; Neil Vasdev
Journal:  Molecules       Date:  2015-05-26       Impact factor: 4.411

5.  L-type Ca²⁺ channel blockade with antihypertensive medication disrupts VTA synaptic plasticity and drug-associated contextual memory.

Authors:  M Degoulet; C E Stelly; K-C Ahn; H Morikawa
Journal:  Mol Psychiatry       Date:  2015-06-23       Impact factor: 15.992

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.